BioSpace News Archive

Flex Pharma Inc. reported financial results for the year ended December 31, 2017 and provided an update on its clinical development and corporate activities.

These will add their extensive experience and networks to PTx team.

Agreement further expands Bionik’s footprint in Asia though Curexo’s sales and distribution network in South Korea; Initial orders for each company’s technology to ship in the coming weeks.

Will Help Fund Future Growth as Company Moves Toward Achieving Positive Operating Cash Flow and Profitability Goals

Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced the European Medicines Agency (EMA) has granted orphan medicinal product (orphan drug) designation to Toca 511 (vocimagene amiretrorepvec) & Toca FC (flucytosine) for the treatment of patients with glioma, a type of brain tumor.

Phase 2a Results Published in Annals of Clinical and Translational Neurology Demonstrate Statistically Significant Improvement in Episodic Memory Function in Patients with Alzheimer’s Disease; Company Initiates Phase 2b (REVERSE-SD) Confirmatory Study with Neflamapimod

- Global phase 2 study will evaluate efficacy and safety of DS-8201 in patients with HER2-expressing advanced colorectal cancer who have received at least two prior lines of standard treatment

New preservation system advances the field of osteochondral allografts, significantly increasing storage life, improving viability, and maximizing tissue used in joint repairs

Issued Claims Cover High Yield Production Process of Phase 2 Antiviral

Stryker’s Spine division today announced that its Tritanium® TL Curved Posterior Lumbar Cage, a 3D-printed interbody fusion cage intended for use as an aid in lumbar fixation, recently received 510(k) clearance from the U.S. Food and Drug Administration.